Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Sanofi SA (ADR) (SNY) Is Trending on Wednesday

Page 1 of 2

Sanofi SA (ADR) (NYSE:SNY) is preparing to oust all the board members of Medivation, Reuters reported on Wednesday, citing people familiar with the matter. The decision comes after Medivation rejected Sanofi’s $9.3 billion acquisition offer last month. Sanofi will use the ‘written consent’ rule which gives Medivation shareholders the ability to replace directors at any time. Medivation ended its negotiations with the Paris-based healthcare company, and demanded a $52.50 per share cash offer, the source added. Sanofi, on the other hand, says that it is willing to raise its offer only if Medivation resumes negotiations. Amid news, Sanofi’s stock has gained 1.90% so far today.

Sanofi SA (ADR) (NYSE:SNY) was in 30 hedge funds’ portfolios at the end of the first quarter of 2016. SNY has experienced a decrease in enthusiasm from smart money in recent months. There were 31 hedge funds in our database with SNY positions at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Mastercard Inc (NYSE:MA), NIKE, Inc. (NYSE:NKE), and BP plc (ADR) (NYSE:BP) to gather more data points.

Follow Sanofi Aventis (NYSE:SNY)
Trade (NYSE:SNY) Now!

In the eyes of most market participants, hedge funds are perceived as underperforming, outdated investment tools of the past. While there are more than 8000 funds with their doors open today, Our researchers choose to focus on the masters of this group, approximately 700 funds. These investment experts shepherd the majority of the hedge fund industry’s total asset base, and by monitoring their matchless investments, Insider Monkey has found a number of investment strategies that have historically exceeded the S&P 500 index. Insider Monkey’s small-cap hedge fund strategy beat the S&P 500 index by 12 percentage points a year for a decade in their back tests.

At the end of the first quarter, a total of 30 of the hedge funds tracked by Insider Monkey were bullish on this stock, down by 3% from the previous quarter. With hedge funds’ capital changing hands, there exists a few key hedge fund managers who were upping their holdings meaningfully (or already accumulated large positions).

Of the funds tracked by Insider Monkey, Fisher Asset Management, managed by Ken Fisher, holds the biggest position in Sanofi SA (ADR) (NYSE:SNY). Fisher Asset Management has a $593 million position in the stock, comprising 1.1% of its 13F portfolio. The second most bullish fund manager is Berkshire Hathaway, managed by Warren Buffett, which holds a $156.9 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Some other members of the smart money that are bullish comprise Francis Chou’s Chou Associates Management, Michael Castor’s Sio Capital and Paul Orlin and Alex Porter’s Amici Capital.

On the next page, we are going to take a look at the funds that unloaded their entire stakes in Sanofi during the first three months of 2016.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!